A significant proportion of patients with PAH remain undertreated on monotherapy, according to data from an Australian registry. A study of more than 1,000 patients with Group 1 PAH enrolled in the Pulmonary Hypertension Society of Australia and New Zealand Registry found 51% were treated with monotherapy and 49% with combination therapy. Importantly, only 66% ...
Huge numbers of patients with PAH miss out on combination therapy
By Mardi Chapman
23 Apr 2020